What Azafaros does

Azafaros B.V. is a clinical-stage biopharmaceutical company founded in 2018 in Leiden, the Netherlands, developing orally administered, brain-penetrant therapies for severe rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) and Niemann-Pick type C (NPC) disease. The company's scientific foundation is an exclusive worldwide license from Leiden University and Amsterdam UMC to a library of patented azasugar compounds, from which its lead clinical candidate nizubaglustat (AZ-3102) was advanced. Nizubaglustat is described as a small molecule with a unique dual mode of action that inhibits both non-lysosomal glucosylceramidase (NLGase/GbA2) and glucosylceramide synthase (GCS), modulating glycosphingolipid metabolism to reduce toxic substrate accumulation in the central nervous system.

The company is operating a single-asset late-stage clinical strategy: it initiated a Phase 1 study in healthy volunteers in April 2021, fully enrolled a 13-patient Phase 2 RAINBOW study in GM2 gangliosidosis and NPC by December 2023, reported positive topline data in July 2024, and began two global Phase 3 NAVIGATE registrational studies in July 2025, with topline Phase 3 data expected in 2028. Azafaros has accumulated a broad set of regulatory designations across jurisdictions, including FDA Orphan Drug, Rare Pediatric Disease, and Fast Track Designations, EMA Orphan Medicinal Product Designations, and a UK MHRA Innovation Passport, which together create material exclusivity incentives and accelerate review pathways upon filing.

Azafaros is currently pre-revenue and has not commercialized any product. Its intended business model is standard orphan-disease pharmaceutical commercialization: prescription drug sales to a small, highly specialized prescriber base of academic medical centers and rare disease clinics, with pricing expected to follow orphan drug economics upon regulatory approval. The company is backed by a syndicate of European healthcare investors led by Forbion (founding investor through Series A and co-lead of Series B) and Jeito Capital (lead of the EUR 132 million Series B in May 2025), with additional participation from Seroba, Pictet Group, BioGeneration Ventures (founding), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. Operations are based in Leiden and Naarden (Netherlands) with a Swiss R&D subsidiary, Azafaros AG, in Basel.

Name

Azafaros

Legal name

Azafaros B.V.

Website

https://azafaros.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Azafaros is a clinical-stage Dutch biotech developing nizubaglustat, an oral brain-penetrant azasugar with a dual NLGase/GCS mechanism, for rare lysosomal storage disorders including GM1/GM2 gangliosidoses and Niemann-Pick type C disease, currently in two global Phase 3 registrational studies.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• Lysosomal storage disorders
• Orphan drug development
• Clinical-stage biotechnology
• Small molecule pharmaceuticals

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Once nizubaglustat receives regulatory approval, revenue will be generated through prescription drug sales for rare lysosomal storage disorders. The company is preparing for drug marketing authorization filings and commercial launch targeting patients with GM1/GM2 gangliosidoses and Niemann-Pick type C disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Azafaros is a clinical-stage biotech company developing nizubaglustat (AZ-3102), an orally available, brain-penetrant azasugar small molecule with a unique dual mode of action inhibiting both NLGase and GCS enzymes. The drug is being advanced through Phase 3 registrational studies (NAVIGATE) for the treatment of rare lysosomal storage disorders including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Product overview

Azafaros is a clinical-stage biotech company with one lead product candidate, nizubaglustat (also referred to as AZ-3102). Nizubaglustat is an orally available, brain-penetrant small molecule azasugar with a unique dual mode of action that modulates glycosphingolipid metabolism. The company is advancing nizubaglustat through Phase 3 registrational studies (NAVIGATE) for the treatment of GM1 and GM2 gangliosidoses and Niemann-Pick type C disease. The company was founded in 2018 and holds an exclusive license from Leiden University and Amsterdam UMC to a library of novel compounds.

Differentiator

Problem solved

Functional benefit

Products and services

• Nizubaglustat (AZ-3102) An orally available, brain-penetrant small molecule azasugar with a unique dual mode of action targeting both NLGase and GCS enzymes, being developed as a potential disease-modifying treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Quantifiable outcome

• 22% survival increase (26 additional days) in Sandhoff disease mouse model at doses as low as 0.2 mg/kg/day
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered research collaborator and core partnership.

• Queen's University (Dr. Jagdeep Walia Laboratory)research collaboratorStrategic or Co-development PartnerCollaboration with Queen's University Department of Pediatrics led by Dr. Jagdeep Walia for preclinical efficacy studies of nizubaglustat in GM2 gangliosidosis (Sandhoff disease mouse model). Published in Journal of Inherited Metabolic Disease.
• Patient Advocacy Organizationscore partnershipStrategic or Co-development PartnerCollaborations with patient organizations including National Tay-Sachs & Allied Diseases Association (NTSAD), National Niemann-Pick Disease Foundation (NNPDF), CATS Foundation, and NPUK for optimizing clinical trial design and patient engagement initiatives.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Abeona Therapeutics: Clinical-stage biotech developing AAV gene therapies for GM1 and GM2 gangliosidoses, directly competing with Azafaros's nizubaglustat in the same lead indications using a different modality (gene therapy vs small molecule).
• Cyclo Therapeutics: Late-stage developer of Trappsol (hydroxypropyl beta cyclodextrin) for Niemann-Pick type C disease, directly competing with nizubaglustat in the NPC indication with a different mechanism of action.

Broad incumbents

• BioMarin Pharmaceutical: Established rare disease leader with multiple approved enzyme replacement and small molecule therapies for lysosomal storage disorders (Vimizim, Naglazyme, Aldurazyme), making it the closest large-cap comparable and likely strategic acquirer for Azafaros.
• Ultragenyx Pharmaceutical: Commercial-stage rare disease company focused on metabolic and neurological disorders, where Azafaros's CEO Stefano Portolano previously served as Head of Europe; comparable commercial model targeting specialized rare disease treatment centers globally.
• Sanofi (Genzyme Rare Disease): Owns the leading LSD franchise (Cerezyme, Fabrazyme, Myozyme, Aldurazyme) and miglustat (via legacy Actelion) for NPC, making it both a competitor in NPC and a likely strategic acquirer for any approved GM1/GM2 therapy.
• Alexion / AstraZeneca Rare Disease: Large rare disease franchise (Soliris, Strensiq, Kanuma) with established commercial infrastructure in ultra-rare metabolic disorders and active BD presence in CNS and LSDs.
• Johnson & Johnson (Janssen / Actelion): Holds miglustat (Zavesca) as the only approved NPC therapy via the Actelion acquisition; the incumbent standard of care in the NPC indication where Azafaros is running a pivotal Phase 3.
• Takeda Pharmaceutical: Large rare disease franchise including Replagal, Elaprase, and Adynovate for LSDs; Azafaros COO previously led rare disease business development at Takeda, making it a logical strategic partner or acquirer.

Emerging players

• IntraBio: Clinical-stage rare disease company with approved and pipeline assets in lysosomal and neurodegenerative disorders, with overlapping interest in NPC and other LSDs where nizubaglustat is being developed.
• Passage Bio: Clinical-stage gene therapy company with CNS-targeted AAV programs including GM1 gangliosidosis, representing an alternative modality competing for the same patient population as nizubaglustat.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/azafaros-b-v

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Azafaros